Skip to main content

Table 2 The alterations of BRM and BRG1 in various cancers

From: BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex—a tumour suppressor or tumour-promoting factor?

Cancer type SMARCA2/BRM Refs. SMARCA4/BRG1 Refs.
Protein expression Genetic alterations Protein expression Genetic alterations
Rhabdoid tumours ↓ (concomitant INI1 loss) Epigenetic silencing [63, 121] Epigenetic silencing [121, 163,164,165]
Lung cancer Promoter polymorphism [64,65,66,67] ↓/(loss) Mutations (LOF) [31, 64, 166, 167]
Renal cell carcinoma (RCC) Mutations [72,73,74] Concomitant loss with INI1 in rhabdoid subtype n/d [168]
Gastric cancer n/d [78, 79] Normal/↑ n/d [78, 169]
Pancreatic cancer ↑/↓ n/d [57, 80, 81] ↑? n/d [80]
Hepatocellular cancer Promoter polymorphism [82, 83] n/d [82]
HNSCC n/d [84] n/d n/d
ACC n/d [86] Normal n/d [86]
Oral cancer n/d n/d Not determined [170]
Breast cancer ↑/↓ Not determined [88, 89] 2% [88, 171]
SCCOHT ↓(loss) n/d [100, 101] ↓/(loss) Somatic and germline mutations [95,96,97,98,99]
OCCC ↓/↑a Mutations [102] n/d n/d
Endometrial cancer Mutations [105] Mutations [105]
Prostate cancer n/d [106, 107] n/d [106, 107]
Melanoma n/d n/d Rare mutations [172, 173]
NMSC Mutations [108] n/d [108]
  1. n/d—no data
  2. aUpregulation of BRM in OCCC corresponds to resistance to cisplatin [103, 104]